

Erlotinib

Catalog No: tcsc0620



Available Sizes

Size: 1g

Size: 2g

Size: 5g

Size: 10g



Specifications

CAS No:

183321-74-6

Formula:

$C_{22}H_{23}N_3O_4$

Pathway:

JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Autophagy

Target:

EGFR;EGFR;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : \geq 50 mg/mL (127.08 mM)

Alternative Names:

NSC 718781;OSI-744;R1415

Observed Molecular Weight:

393.44


Product Description

Erlotinib inhibits purified **EGFR** kinase with an **IC₅₀** of 2 nM.

IC50 & Target: IC50: 2 nM (EGFR)^[1]

In Vitro: Erlotinib (CP-358,774) is also a potent inhibitor of the recombinant intracellular (kinase) domain of the EGFR, with an IC₅₀ of 1 nM. The proliferation of DiFi cells is strongly inhibited by Erlotinib with an IC₅₀ of 100 nM for an 8-day proliferation assay^[1]. The combination of B-DIM and Erlotinib (2 μM) results in a significant inhibition of colony formation in BxPC-3 cells when compared with either agent alone. The combination of B-DIM and Erlotinib (2 μM) results in a significant induction of apoptosis only in BxPC-3 cells when compare with the apoptotic effect of either agent alone^[2].

In Vivo: Under the experimental conditions, the combination of B-DIM and Erlotinib (50 mg/kg, i.p.) treatment shows significant decrease (P [2]. Erlotinib (20 mg/kg, p.o.) significantly attenuates Cisplatin (CP)-induced body weight (BW) loss when compared to the CP+vehicle (V) rats (P[3]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!